脓毒症休克中按舒张压和脉压分层的升压药启动时间与临床结局:前瞻性多中心队列研究的回顾性分析
该研究为前瞻性多中心脓毒症注册数据(2019–2024)的回顾性分析,纳入1104例急诊就诊的成人脓毒症休克患者,以分诊至去甲肾上腺素启动时间≤25 min定义为早期使用,主要终点为住院死亡率。结果显示早期去甲肾上腺素仅在舒张压<50 mmHg者中与较低死亡率相关,舒张压≥50 mmHg者无死亡率获益;舒张压<40、<44 mmHg等更极端阈值下关联更强。脉压进一步细化风险:低舒张压组中宽脉压(≥25 mmHg)与立即升压的生存关联最明显,窄脉压无明确获益。作者认为简单床旁指标(舒张压和脉压)可指导个体化复苏,帮助决定启动升压药还是先强调前负荷或正性肌力。
要点
- 早期去甲肾上腺素(分诊至启动≤25 min)仅在舒张压<50 mmHg的脓毒症休克患者中与住院死亡率降低相关,舒张压≥50 mmHg者无死亡率获益。
- 舒张压阈值越低关联越强:<40 mmHg和<44 mmHg时早期升压的生存关联比<50 mmHg更明显。
- 低舒张压组内,宽脉压(≥25 mmHg)者立即升压的生存关联最明显,窄脉压(<25 mmHg)者无明确获益。
- 作者认为床旁舒张压和脉压可帮助决定是立即启动升压药,还是先强调前负荷或正性肌力。
适用人群与场景
- 2019–2024年全国脓毒症注册研究中,急诊就诊的成人脓毒症休克患者,共1104例。
- 按启动升压药前舒张压分层:<50 mmHg vs ≥50 mmHg;次要按脉压分层:<25 mmHg vs ≥25 mmHg。
诊断标准与关键阈值
- 早期使用定义:分诊至去甲肾上腺素启动时间≤25 min,该界值由限制性立方样条支持并经先验分类。
- 敏感性分析探索的替代舒张压阈值:<40 mmHg、<44 mmHg。
研究设计与关键结果
- 研究类型:前瞻性多中心队列研究的回顾性分析,样本量1104例,数据来自2019–2024年全国脓毒症注册研究。
- 主要终点住院死亡率:早期去甲肾上腺素仅在低舒张压(<50 mmHg)患者中与较低死亡率相关,舒张压≥50 mmHg者无死亡率获益。
- 舒张压阈值越极端关联越强:<40 mmHg和<44 mmHg时早期升压与死亡率的关联比<50 mmHg更强。
- 低舒张压组内脉压分层:宽脉压(≥25 mmHg)者立即升压的生存关联最明显,窄脉压(<25 mmHg)者无明确获益。
- 多变量模型校正了人口学、合并症、疾病严重度(SOFA)、3小时脓毒症集束化治疗完成情况和机械通气;敏感性和亚组分析结果方向一致。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列数据的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,简单的床旁测量(舒张压和脉压)可指导个体化复苏,帮助临床医生决定是启动升压药还是先强调前负荷或正性肌力。
- 作者认为,舒张压明显降低(尤其伴宽脉压≥25 mmHg)时早期去甲肾上腺素似乎有益;舒张压保留或脉压窄时早期升压的必要性较低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal timing of vasopressor initiation in septic shock remains uncertain, and mixed trial results may reflect unmeasured hemodynamic heterogeneity. We hypothesized that the association between early norepinephrine and mortality differs by bedside hemodynamic phenotype, as characterized by diastolic blood pressure (DBP) and pulse pressure (PP). METHODS: We conducted a retrospective analysis of prospectively collected data from a national sepsis registry (2019–2024). Adults with septic shock presenting to emergency departments were included. Time-to-vasopressor was defined as the time from triage to norepinephrine initiation; restricted cubic splines supported an a priori classification of “early” use as ≤ 25 min. The primary outcome was in-hospital mortality. Patients were stratified by pre-vasopressor DBP (< 50 vs. ≥ 50 mmHg) and, secondarily, by PP (< 25 vs. ≥ 25 mmHg). Multivariable models adjusted for demographics, comorbidities, illness severity (SOFA), three-hour sepsis bundle completion, and mechanical ventilation. Sensitivity analyses explored alternative DBP thresholds (< 40, < 44 mmHg), and subgroup analyses assessed effect consistency. RESULTS: Among 1,104 patients, early norepinephrine was associated with lower mortality only in those with low DBP; there was no mortality benefit when DBP was ≥ 50 mmHg. Mortality associations were stronger at more extreme diastolic hypotension thresholds (< 40 and < 44 mmHg). Hemodynamic phenotyping with PP further refined risk: within the low-DBP group, a wide PP (≥ 25 mmHg) was associated with the most pronounced survival association from immediate vasopressors, whereas a narrow PP showed no clear benefit. Results were directionally consistent across sensitivity and subgroup analyses. CONCLUSIONS: The relationship between vasopressor timing and outcomes in septic shock is hemodynamic phenotype dependent. Early norepinephrine appears beneficial when DBP is markedly low, particularly with wide PP, and less critical when DBP is preserved or PP is narrow. Simple bedside measurements (DBP and PP) can guide individualized resuscitation, helping clinicians decide whether to initiate vasopressors or initially emphasize preload or inotropy. TRIAL REGISTRATION: Not applicable.
参考来源
- Ko RE, Kang D, Kim WY, et al. Time-to-vasopressors and clinical outcome by level of diastolic blood pressure and pulse pressure in patients with septic shock: a retrospective analysis of prospective multicenter cohort study. Crit Care. 2026. PMID: 41593462. doi:10.1186/s13054-026-05859-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。